Skip to content

Frontiers in Psychiatry

ISSN 1664-0640

601 papers in the library · 9,228 citations · publishing 2010-2026

Papers

Sort Most recent Most cited

Effect of fear of missing out on learning burnout in medical students: a moderated mediation.

Frontiers in Psychiatry 2023 Xin Ye, Yang Li, Yang Liu et al.

Learning burnout has a significant negative impact on students' academic performance and professional development, which has been exacerbated by the growing trend of problematic smartphone use, such as smartphone addiction, among young people. Recently, the literature on excessive social media use has revealed a critical role of fear of missing out. Objective The purpose of this study was to...

The voice characterisation checklist: psychometric properties of a brief clinical assessment of voices as social agents.

Frontiers in Psychiatry 2023 Clementine J Edwards, Oliver Owrid, Lucy Miller et al.

There is growing interest in tailoring psychological interventions for distressing voices and a need for reliable tools to assess phenomenological features which might influence treatment response. This study examines the reliability and internal consistency of the Voice Characterisation Checklist (VoCC), a novel 10-item tool which assesses degree of voice characterisation, identified as...

Effects of a brief mindfulness meditation practice on Pavlovian-to-instrumental transfer in alcohol use disorder - a pilot study.

Frontiers in Psychiatry 2023 Annika Rosenthal, Maria Garbusow, Nina Romanczuk-Seiferth et al.

Pavlovian conditioned contextual cues have been suggested to modulate instrumental action and might explain maladaptive behavior such as relapse in participants suffering from alcohol use disorder (AUD). Pavlovian-to-Instrumental transfer (PIT) experimentally assesses the magnitude of this context-dependent effect and studies have shown a larger PIT effect in AUD populations. Taken this into...

The time scales of irreversibility in spontaneous brain activity are altered in obsessive compulsive disorder.

Frontiers in Psychiatry 2023 Davide Bernardi, David Shannahoff‐Khalsa, Jeff Sale et al.

We study how obsessive-compulsive disorder (OCD) affects the complexity and time-reversal symmetry-breaking (irreversibility) of the brain resting-state activity as measured by magnetoencephalography (MEG). Comparing MEG recordings from OCD patients and age/sex matched control subjects, we find that irreversibility is more concentrated at faster time scales and more uniformly distributed across...

DOI: 10.3389/fpsyt.2023.1158404 (opens in new tab) Full text (opens in new tab) Meditation Kundalini yoga Dynamical disease Obsessive-compulsive disorder +4

Effect of mindfulness-based cognitive therapy vs. psychoeducational intervention on plasma brain-derived neurotrophic factor and cognitive function in bipolar patients: a randomized controlled trial.

Frontiers in Psychiatry 2023 Diego Carracedo-Sanchidrian, Consuelo De Dios-Perrino, Carmen Bayon-Perez et al.

Few controlled trials have assessed the benefits of Mindfulness Based Cognitive Therapy (MBCT) on cognitive functions and brain-derived neurotrophic factor (BDNF) in bipolar disorder (BD). This study aims to evaluate the impact of MBCT adjunctive treatment on these variables. Main hypothesis was that MBCT would improve cognitive functioning and BDNF more than Psychoeducation and TAU....

DOI: 10.3389/fpsyt.2023.1279342 (opens in new tab) Full text (opens in new tab) Brainderived neurotrophic factor Bipolar disorder Cognition Cognitive impairment +1

Prospective, longitudinal study to isolate the impacts of marijuana use on neurocognitive functioning in adolescents.

Frontiers in Psychiatry 2023 Wen Ren, Diana H Fishbein

Policies to legalize possession and use of marijuana have been increasingly supported across the United States. Although there are restrictions on use in minors, many substance abuse scientists anticipate that these policy changes may alter use patterns among adolescents due to its wider availability and a softening of beliefs about its potentially harmful consequences. Despite the possibility...

DOI: 10.3389/fpsyt.2023.1048791 (opens in new tab) Full text (opens in new tab) Adolescence Emotion recognition Legalization Longitudinal +3

A comparison of the antianhedonic effects of repeated ketamine infusions in melancholic and non-melancholic depression

Frontiers in Psychiatry December 22, 2022 Wei Zheng, Xin-Hu Yang, Li-Mei Gu et al. 4 citations

ObjectivesMelancholic depression may respond differently to certain treatments. The aim of this study was to compare the antianhedonic effects of six intravenous injections of 0.5 mg/kg ketamine in patients with melancholic and non-melancholic depression, which remain largely unknown.MethodsIndividuals experiencing melancholic (n = 30) and non-melancholic (n = 105) depression were recruited and...

The economics of psychedelic-assisted therapies: A research agenda

Frontiers in Psychiatry December 5, 2022 Elliot Marseille, Stefano Bertozzi, James G. Kahn 51 citations

After a long hiatus, psychiatry is undergoing a resurgence of interest in psychedelic drugs as therapy for a wide range of mental health disorders Accumulating clinical evidence suggests substantial potential for psychedelics used in a therapeutic context, as treatment for, among other disorders, depression, post-traumatic stress disorder (PTSD), and addictions to tobacco, opioids and alcohol....

DOI: 10.3389/fpsyt.2022.1025726 (opens in new tab) MDMA Psilocybin Cost-effectiveness Health economics +5

Moderators of ayahuasca’s biological antidepressant action

Frontiers in Psychiatry December 5, 2022 Geovan Menezes de Sousa, Vagner Deuel de Oliveira Tavares, Ana Cecília de Menezes Galvão et al. 14 citations

Introduction The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol...

DOI: 10.3389/fpsyt.2022.1033816 (opens in new tab) Cortisol Inflammation Psychedelics hallucinogens Entheogens +7

Lower-dose psycholytic therapy – A neglected approach

Frontiers in Psychiatry December 2, 2022 Torsten Passie, Jeffrey Guss, Rainer Krähenmann 71 citations

Lysergic acid diethylamide (LSD) and similar psychoactive drugs have been used in psychotherapy since 1949, when the first clinical study with lower-dose LSD showed therapeutically relevant effects. This caused an intense interest among psychotherapists and researchers, alike, on an international scale. In 1960, the use of serial lower-dose LSD/psilocybin sessions in a psychoanalytical...

Therapeutic use of psilocybin: Practical considerations for dosing and administration

Frontiers in Psychiatry December 1, 2022 Jagpaul Kaur Deol, Caroline A. Maccallum, Lindsay A. Lo et al. 95 citations

The interest in psilocybin as a therapeutic approach has grown exponentially in recent years. Despite increasing access, there remains a lack of practical guidance on the topic for health care professionals. This is particularly concerning given the medical complexity and vulnerable nature of patients for whom psilocybin-assisted psychotherapy may be considered. This article aims to provide...

DOI: 10.3389/fpsyt.2022.1040217 (opens in new tab) Psilocybin Dosing Health professionals Health care +5

Reactivations after 5-methoxy-N,N-dimethyltryptamine use in naturalistic settings: An initial exploratory analysis of the phenomenon’s predictors and its emotional valence

Frontiers in Psychiatry November 29, 2022 Ana María Ortiz Bernal, Charles L. Raison, Rafael Lancelotta et al. 26 citations

Background The psychedelic 5-MeO-DMT has shown clinical potential due to its short duration and ability to induce mystical experiences. However, a phenomenon known as “reactivations” (similar to “flashbacks”) is a poorly understood and frequently reported phenomenon which appears associated with 5-MeO-DMT use and warranted further investigation. Aims This study examined whether differences in...

DOI: 10.3389/fpsyt.2022.1049643 (opens in new tab) Valence chemistry Logistic regression Descriptive statistics Clinical psychology +2

A survey of drug liking and cravings in patients using sublingual or intranasal ketamine for treatment resistant depression: A preliminary evaluation of real world addictive potential

Frontiers in Psychiatry November 17, 2022 Brittany Chubbs, Jay Wang, S. Archer et al.

Ketamine has gained rapid popularity as a treatment option for treatment resistant depression (TRD). Though seen only in limited contexts, ketamine is a potential drug of abuse, addiction and diversion. Clinical ketamine studies to date have not systematically evaluated factors relevant to addiction risk in patients with TRD, but in treating patients with ketamine, risks of potential harms...

Mindfulness-based online intervention on mental health among undergraduate nursing students during coronavirus disease 2019 pandemic in Beijing, China: A randomized controlled trial.

Frontiers in Psychiatry November 16, 2022 Zhenwei Dai, Shu Jing, Hao Wang et al.

Objective: To evaluate the effect of mindfulness intervention on improving mental health among undergraduate nursing students during the coronavirus disease 2019 (COVID-19) pandemic in China. Methods: An online mindfulness intervention course named Mindfulness Living With Challenge (MLWC) was developed by the research team, and a randomized controlled trial using MLWC among Chinese...

Rumination and “hot” executive function of middle school students during the COVID-19 pandemic: A moderated mediation model of depression and mindfulness

Frontiers in Psychiatry November 14, 2022 Ying Li, Gui-Ping Qu, Huiyan Kong et al.

Background The outbreak of COVID-19 had a widely negative effect on adolescents’ academics, stress, and mental health. At a critical period of cortical development, adolescents’ cognition levels are highly developed, while the ability of emotion control is not developed at the same pace. Faced with negative emotions such as stress and social loneliness caused by COVID-19, adolescents’ “hot”...

The multidimensional assessment of interoceptive awareness, version 2: Translation and psychometric properties of the Chinese version

Frontiers in Psychiatry November 11, 2022 Binyu Teng, Dan Wang, Conghui Su et al. 38 citations

BackgroundThe Multidimensional Assessment of Interoceptive Awareness (MAIA) is a self-report questionnaire developed by Dr. Mehling that has been widely used to assess multiple dimensions of interoceptive awareness. To further improve the MAIA, Mehling developed the Multidimensional Assessment of Interoceptive Awareness, Version 2 (MAIA-2). The goal of this study is to systematically translate...

DOI: 10.3389/fpsyt.2022.970982 (opens in new tab) Full text (opens in new tab) Reliability Validity Interoception Interoceptive awareness +1

MDMA for the treatment of misophonia, a proposal.

Frontiers in Psychiatry November 10, 2022

Misophonia is a disorder characterized by negative physical and emotional reactions to certain trigger sounds, such as chewing food. Up to 50% of population samples endorse some symptoms of misophonia, with about 20% having symptoms that impair normal life functioning. Most misophonia patients exhibit intense negative emotions and autonomic arousal (the fight-flight-freeze response) in response...

Therapeutic setting as an essential component of psychedelic research methodology: Reporting recommendations emerging from clinical trials of 3,4-methylenedioxymethamphetamine for post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Lauren Okano, Bri Deyo, Alida Brandenburg et al. 24 citations

Research of psychedelic assisted therapies is at an all-time high, though few studies highlight extra-pharmacological factors that may affect treatment efficacy. One critical set of attributes includes the therapeutic setting itself, which describe the physical and socio-cultural environments in which the drug-assisted session occurs. Despite enduring consensus of the influence of setting,...

DOI: 10.3389/fpsyt.2022.965641 (opens in new tab) Traumatic stress Psychotherapist Clinical trial Clinical psychology

MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder

Frontiers in Psychiatry November 3, 2022 Devon Christie, Berra Yazar-Klosinski, Ekaterina Nosova et al. 8 citations

IntroductionIncreasing evidence demonstrates 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy (MDMA-AT) may be a safe and effective treatment for post-traumatic stress disorder (PTSD). There is growing interest in MDMA-AT to address a range of other health challenges. Chronic pain and PTSD are frequently comorbid, reciprocally interdependent conditions, though the possible role of...

Study protocol for “MDMA-assisted therapy as a treatment for major depressive disorder: A proof of principle study”

Frontiers in Psychiatry October 26, 2022 Tor-Morten Kvam, Ivar W Goksøyr, Lowan H. Stewart et al. 11 citations

Background Major depressive disorder (MDD) is a world-leading cause of disability. The available treatments are not effective in all patients, and there is a significant need for more effective treatment options. Here we present the protocol for an investigator-initiated and publicly funded trial of MDMA-assisted therapy (MDMA-AT) for MDD. This single-site, open-label study investigates the...

A proposed mechanism for the MDMA-mediated extinction of traumatic memories in PTSD patients treated with MDMA-assisted therapy

Frontiers in Psychiatry October 12, 2022 Robert J Sottile, Thomas Vida 30 citations

Post-traumatic stress disorder (PTSD) is a devastating psychiatric disorder afflicting millions of people around the world. Characterized by severe anxiety, intrusive thoughts, pervasive nightmares, an assortment of somatic symptoms, associations with severe long-term health problems, and an elevated risk of suicide, as much as 40–70% of patients suffer from refractory disease....

MDMA-assisted psychotherapy; Inclusion of transgender and gender diverse people in the frontiers of PTSD treatment trials

Frontiers in Psychiatry October 10, 2022 Christopher S. Stauffer, Melanie Brown, Dee Adams et al. 40 citations

Introduction Transgender and gender diverse (TGD) people experience stigma, discrimination, trauma, and post-traumatic stress disorder (PTSD) at higher rates compared to the general population; however, TGD people have been underrepresented in PTSD research. Clinical trials of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy demonstrate promising safety and efficacy for the...

DOI: 10.3389/fpsyt.2022.932605 (opens in new tab) MDMA Mental health Transgender Clinical psychology +5

3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs

Frontiers in Psychiatry October 3, 2022 Jordi Camarasa, Pol Puigseslloses, Edurne Urquizu et al. 5 citations

The utility of classical drugs used to treat psychiatric disorders (e.g., antidepressants, anxiolytics) is often limited by issues of lack of efficacy, delayed onset of action or side effects. Psychoactive substances have a long history of being used as tools to alter consciousness and as a gateway to approach the unknown and the divinities. These substances were initially obtained from plants...

Safety, effectiveness and tolerability of sublingual ketamine in depression and anxiety: A retrospective study of off-label, at-home use

Frontiers in Psychiatry September 28, 2022 K. Hassan, W. Struthers, Aditya Sankarabhotla et al. 25 citations

Intravenous and intranasal ketamine have been shown to be effective therapeutic options in patients suffering from treatment-resistant depression (TRD). The use of sublingual (SL), rapid dissolve ketamine tablets (RDT) offers a novel approach for delivery for mental health indications. This study assessed the effectiveness and safety of self-administration of off-label, SL, rapid dissolve...

Facing death, returning to life: A qualitative analysis of MDMA-assisted therapy for anxiety associated with life-threatening illness

Frontiers in Psychiatry September 27, 2022 William P. Barone, Michiko Mitsunaga-Whitten, Lia Osunfunláyò Blaustein et al. 14 citations

Anxiety associated with life-threatening illness (LTI) is a pervasive mental health issue with a wide impact. A spectrum of traditional pharmacotherapies and psychotherapies are available, but offer varying success in reducing symptoms and improving quality of life. We explore a novel therapy for this condition by assessing prominent thematic elements from participant narrative accounts of a...

DOI: 10.3389/fpsyt.2022.944849 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Therapy Life-threatening illness Psycho-existential distress Existential anxiety +1